Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 592 results for women's health

  1. Maternal request for caesarean birth: What support or psychological interventions would be appropriate for women who have a fear of vaginal childbirth and request a caesarean birth?

    birth: What support or psychological interventions would be appropriate for women who have a fear of vaginal childbirth and request a...

    Research recommendation
    Published
    24 April 2023

  2. Tezepelumab for treating severe asthma (TA880)

    Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.

    Technology appraisal guidance
    Published
    20 April 2023
    View recommendations

    Sections for TA880

  3. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST25

  4. Hundreds of people are set to receive the first immunotherapy drug for advanced cervical cancer through the Cancer Drugs Fund

    Hundreds of people with cervical cancer are set to receive the first immunotherapy drug for an advanced form of the disease as NICE publishes final draft guidance today (Wednesday 29 March 2023) recommending its use in the Cancer Drugs Fund (CDF).

    News
    Published
    29 March 2023

  5. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)

    NICE has developed a medtech innovation briefing (MIB) on QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) .

    Medtech innovation briefing
    Published
    7 March 2023

  6. Type 1 diabetes in adults (QS208)

    This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    2 March 2023
    View quality statements

    Sections for QS208

  7. Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)

    Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.

    Technology appraisal guidance
    Published
    1 March 2023
    View recommendations

    Sections for TA874

  8. Abortion care. Patient decision aid on choosing between medical or surgical abortion before 14 weeks

    Abortion Choosing between medical or surgical abortion before 14 weeks Most women and girls who have an abortion can choose how it will...

  9. Abortion care. Patient decision aid on choosing between medical or surgical abortion from 14 weeks up to 24 weeks

    Choosing between medical or surgical abortion from 14 weeks up to 24 weeks Most women and girls who have an abortion can choose how it...

  10. New NICE quality standard identifies improvements in UTI diagnosis for women

    Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms according to a new quality standard published by NICE today (15 February 2023).

    News
    Published
    15 February 2023

  11. Urinary tract infections in adults (QS90)

    This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    15 February 2023
    View quality statements

    Sections for QS90

  12. Antenatal care (QS22)

    This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    14 February 2023
    View quality statements

    Sections for QS22

  13. Regorafenib for previously treated metastatic colorectal cancer (TA866)

    Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    8 February 2023
    View recommendations

    Sections for TA866

  14. Updates from our last maternity report

    neonatal care Previous: Introduction Next: Maternity and mental health In May 2018 we published the NICEimpact report on maternity

  15. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go . It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking. The guideline brings together and updates all NICE's previous guidelines on using tobacco, including smokeless tobacco . It covers nicotine replacement therapy and e-cigarettes to help people stop smoking or reduce their harm from smoking. It does not cover using tobacco products such as ‘heat not burn’ tobacco.

    NICE guideline
    Last updated
    16 January 2023

    Sections for NG209